Accumulation of eosinophils is the hallmark of several medical conditions such as infections and systemic diseases. A number of chemokines stimulate the proliferation, migration and accumulation of eosinophils at the site of inflammation. Eotaxin-2 is chemoattractant that selectively acts on eosinophils and has minimal effect on other leukocytes. It is secreted in response to TNF-α, IL-5 or IL-3. The effect of Eotaxin is mediated by specific eotaxin receptor that induces activation of Gi proteins, MAPK signaling and involves changes in intracellular calcium levels and cytoskeletal reorganization. Eotaxin receptor is present on eosinophils, basophils and T-helper cells. Eotaxin coordinates the accumulation of these cells in response to allergic inflammation and homing of eosinophils to gastrointestinal tract and mucosal tissues Monoclonal Anti-Eotaxin-2 (MPIF-2) recognizes recombinant human eotaxin-2, less than 0.03 % cross-reactivity with recombinant human eotaxin, MIP-1α, and MCP-3.
Immunogen
recombinant human eotaxin-2.
Application
Anti-eotaxin-2 antibody may be used for neutralization assays at a working concentration of 1-5 μg/ml in the presence of 100 ng/ml of human recombinant eotaxin-2. The antibody is suitable for immunoblotting at 1-2 μg/ml concentration. For capture ELISA, a final concentration of 2 μg/ml may be used.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline
Preparation Note
Purified using protein G
Analysis Note
The antibody neutralizes the biological activity of recombinant human eotaxin-2. It exhibits less than 0.03% cross-reactivity with recombinant human eotaxin, MIP-1α, and MCP-3.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
The Journal of clinical investigation, 103(12), 1719-1727 (1999-06-22)
The histological identification of increased eosinophils in the gastrointestinal tract occurs in numerous clinical disorders; however, there is a limited understanding of the mechanisms regulating eosinophil trafficking into this mucosal surface. The results presented in this study characterize the processes
The p38 MAP kinase and myosin light chain kinase (MLCK) critically regulate eosinophil chemotaxis in response to eotaxin
Alam R et al
The Journal of Allergy and Clinical Immunology, 103, S56-S56 (1999)
Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues.
M E Rothenberg
American journal of respiratory cell and molecular biology, 21(3), 291-295 (1999-08-26)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.